首页
MALAYSIA

Search result for

Concise Prescribing Info
Distributor
Contents
Ertugliflozin
Indications / Uses
Adjunct to diet & exercise to improve glycaemic control in adults ≥18 yr w/ type 2 DM as monotherapy in patients for whom use of metformin is considered inappropriate due to intolerance or CI, or in addition to other medicinal products for the treatment of diabetes.
Click to view detailed Steglatro Indications/Uses
Dosage / Direction for Use
Recommended starting dose: 5 mg once daily, may be increased to 15 mg once daily if needed.
Click to view detailed Steglatro Dosage/Direction for Use
Overdosage
View Steglatro overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Take in the morning.
Contraindications
Special Precautions
Not to be used for type 1 DM. Discontinue use if diabetic ketoacidosis & necrotising perineum fasciitis (Fournier's gangrene) is suspected & if eGFR persistently <45 mL/min/1.73 m2 or CrCl persistently <45 mL/min. Not to be initiated in patients w/ eGFR <60 mL/min/1.73 m2 or CrCl <60 mL/min. Vol depletion risk in patients on diuretics, antihypertensives or w/ history of hypotension. Patients w/ low β-cell function reserve, conditions that lead to restricted food intake or severe dehydration, increased/decreased insulin dose due to acute medical illness, surgery or alcohol abuse; events which may precede amputation eg, lower-extremity skin ulcer, infection, osteomyelitis or gangrene; increased risk of genital mycotic infections; UTI; cardiac failure (NYHA class I-IV). False positive result for glucose test. Interference w/ 1,5-anhydroglucitol assay. Concomitant use w/ insulin & insulin secretagogues. Monitor renal function prior to & during treatment. Monitor vol status & electrolytes during therapy. Counsel patients on routine preventative foot care. Galactose intolerance, total lactase deficiency, glucose-galactose malabsorption. May affect ability to drive & use machines. Not to be used in severe renal impairment, end-stage renal disease or receiving dialysis. Not recommended in severe hepatic impairment. Not to be used during pregnancy & lactation. Childn <18 yr. Elderly ≥65 yr.
Click to view detailed Steglatro Special Precautions
Side Effects / Adverse Reactions
Vulvovag & other female genital mycotic infections. Balanitis candida & other male genital mycotic infections; hypoglycaemia; vol depletion; increased urination; vulvovag pruritus; thirst; changed serum lipids, increased Hb & BUN.
Click to view detailed Steglatro Side Effects / Adverse Reactions
Interactions
Increased risk of dehydration & hypotension w/ diuretics. Increased risk of hypoglycaemia w/ insulin &/or insulin secretagogues eg, sulphonylureas.
Caution For Usage
For caution against possible variation of physical aspect of medicine... click to view detailed Steglatro Caution For Usage
Storage
View Steglatro storage conditions for details to ensure optimal shelf-life.
Description
View Steglatro description for details of the chemical structure and excipients (inactive components).
Mechanism of Action
View Steglatro mechanism of action for pharmacodynamics and pharmacokinetics details.
ATC Classification
A10BK04 - ertugliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.
Presentation / Packing
FormPacking/Price
Steglatro FC tab 10 mg
28's
Steglatro FC tab 5 mg
28's



ck棋牌Steglatro6002174CL_4c.GIF

Editor's Recommendations

Drug Index A to Z
Browse Alphabetically (Brand)
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Browse Alphabetically (Generic)
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 
Connect With Us
 
 
Download FREE MIMS Apps
 
Node#1
Please wait...

友情链接:11选5彩乐乐 内蒙11选5走势图 吉林快3开奖结果 天津11选5走势图 山西11选5走势图 广东体育彩票11选5 江苏11选5基本走势图 浙江体彩11选5 湖北体彩新11选5走势图